Regular Article
Establishment and Characterization of Two Human Ovarian Clear Cell Adenocarcinoma Lines from Metastatic Lesions with Different Properties

https://doi.org/10.1006/gyno.1995.1097Get rights and content

Abstract

Two permanent human ovarian clear cell adenocarcinoma lines (OVISE and OVTOKO) were established from metastatic tumors of two patients who were treated with five to six courses of CAP chemotherapy. The two cell lines grow on monolayers and showed a variety in both size and shape: small or moderately sized cuboidal cells, columnar cells, spindle-shaped cells, and malignant tumor giant cells. The cell lines have been in culture for 4 to 6 years, the passage number varying from 160 to 220. The mean population-doubling time of the two cells was 60 to 70 hr. The OVISE cells shed tumor-associated antigens CA19-9, CA125, and TPA in the culture medium, whereas the OVTOKO cells did not secrete them at detectable levels. Immunohistochemical analysis showed that coexpression of cytokeratins and vimentin was preserved in the two cell lines, which is a feature of cultured epithelial origin. Cytokeratin polypeptides 7, 8, 18, and 19 were expressed in both cell lines. The EGF receptor was more intensely expressed in the OVTOKO cells than in the OVISE cells. The estrogen and progesterone receptors were negative in both cell lines. The two cell lines showed no chemosensitivity to anticancer drugs including cisplatin, doxorubicin, cyclophosphamide, and etoposide. Hetero-transplantation of the two cell lines reflected the origin of cells. Intraperitoneal transplantation of the OVTOKO cells yielded peritoneal implantation and distant metastasis, whereas that of the OVISE cells showed no dissemination and metastasis. These new ovarian clear cell adenocarcinoma lines will provide a relevant experimental system for further investigations into the intrinsic alterations responsible for malignant progression and chemoresistance.

References (0)

Cited by (51)

  • The primary effect on the proteome of ARID1A-mutated ovarian clear cell carcinoma is downregulation of the mevalonate pathway at the post-transcriptional level

    2016, Molecular and Cellular Proteomics
    Citation Excerpt :

    We performed a complementary proteomics analysis to validate the effects of ARID1A knockout observed in OVCA429 in an alternative biological context. Wild-type ARID1A was reintroduced into the ARID1A-mutated OCCC cell line OVISE (38), which completely lacks expression of ARID1A protein (17), using a tetracycline-inducible construct (supplemental Fig. S3). This experimental approach was recently used to study the transcriptional effects of ectopic expression of wild-type ARID1A in OVISE cells (20).

  • Clear cell carcinoma of the ovary: A review of the literature

    2012, Gynecologic Oncology
    Citation Excerpt :

    The study by Gorai et al. supports this rationale. In this study, ovarian CCC cells exhibited resistance to cisplatin [89]. However, given the retrospective nature of our study and the others cited, firm conclusions on this relationship cannot be reached.

  • Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis

    2011, Gynecologic Oncology
    Citation Excerpt :

    One potential mechanism related to the poor overall survival in CCC may be insensitivity to platinum-based chemotherapy, which is also related to chemoresistance [36] relative to non-CCC [6,16,17,24,28,31,37]. For example, an in vitro study indicated that CCC cells exhibited resistance to platinum [38] and Sugiyama et al. reported that the response rate to platinum-based chemotherapy in patients with CCC was significantly lower than in patients with serous EOC (11.1% vs. 72.5%) [17]. Combination chemotherapy with platinum plus paclitaxel-based chemotherapy has been accepted as the standard regimen for EOC [39].

View all citing articles on Scopus
View full text